Introduction
============

Early physiologists ascribed the regulation of the vascular tone to hormones released by specific endocrine glands or to the autonomous nervous system. A singular breakthrough against this notion was the proposal made in the mid of last century by Spanish physicians who observed the blood pressure effects of arterial extract injections. They proposed the existence of an endocrine function within the vascular wall. The hormonal functions were not yet assigned to specific vascular structures but were considered endocrine, rather than paracrine ([@B71]). The notion of paracrine secretion was introduced shortly after for its convenience in distinguishing gastrointestinal hormones acting locally from hormones with systemic action ([@B45]). However, the term "paracrine" took quite a long time to become of common use.

It is of justice to admit that before the unprecedented advance made with the introduction of endothelium-derived relaxing factor (EDRF) ([@B48]), later identified as nitric oxide (NO), the discovery of prostacyclin should be recognized as the earliest approach to a tissue-specific release of a vasomotor mediator from and toward the arterial wall itself ([@B93], [@B95]). The notion of endothelial cells releasing substances that preferentially affect smooth muscle cells, which is the sense of paracrine control, was extended during the eighties to other substances, such as NO, prostanoids or endothelin. Under this point of view, the endothelial cell was designated as a full endocrine organ ([@B136]). Over the years, other vascular cells were included as paracrine regulatory cells. Incongruous as it may seem, the first non-endothelial vascular tissue to qualify as paracrine is the distant perivascular fat tissue ([@B128]) rather that the closer adventitial fibroblast. However, these precocious scientists could not see the surge of research on perivascular fat until 2002, when the first adipocyte-derived vasoactive factor was described ([@B82]). In the meantime, new roles were assigned to adventitial cells as a source of paracrine substances ([@B106]) and a new concept in the control of vasomotion based on an outside-to-inside regulation surged.

This review is centered in the paracrine vascular self-regulation of its own diameter. We have left aside the hormonal and nervous regulation as well as gasotransmission by molecules other than NO, which has been extensively reviewed ([@B15]; [@B35]). Is important to stress that it is not always easy to establish when a mediator is solely paracrine or has endocrine properties as well. [Figure 1](#F1){ref-type="fig"} shows the vessel's layers and the paracrine substances produced by each one and [Table 1](#T1){ref-type="table"} displays in chronological order the major events of vascular paracrine research and discovery.

![Functional anatomy of a vessel showing the three classic *tunicae* plus the fourth proposed layer, PVAT or *tunica adiposa*. The paracrine substances produced by each layer are depicted. Prostacyclin (PGI~2~), thromboxane A~2~ (TXA~2~), prostaglandin E~2~ (PGE~2~), endothelium-derived hyperpolarizing factors (EDHFs), endothelin-1 (ET-1), angiotensin II (AT II), adipose-derived relaxing factor (ADRF).](fphys-10-00729-g001){#F1}

###### 

Major events of vascular paracrine finding chronologically ordered.

  Event                                                                                          References
  ---------------------------------------------------------------------------------------------- ----------------
  Discovery of a vasodilatory prostaglandin synthesized and released by the vessel wall          [@B93]
  Chemical structure and coining of the term: prostacyclin                                       [@B148]
  The endothelium as the most abundant source of prostacyclin                                    [@B94]
  Activation of guanylate cyclase by NO and nitrocompounds                                       [@B73]
  Discovery of the role of endothelium as a source of vasodilating substances upon stimulation   [@B48]
  Earliest confirming reports                                                                    [@B3]; [@B29]
  Endothelium-dependent vasoconstriction                                                         [@B28]
  First use of the acronym: EDRF                                                                 [@B21]
  First use of the term: nitrovasodilators                                                       [@B113]
  Endothelium-dependent hyperpolarization of smooth muscle                                       [@B12]
  Existence of an endothelial cell-derived vasoconstrictor substance of polypeptidic nature      [@B66]
  Evidence of endothelial release of a diffusible vasoconstrictor substance                      [@B121]
  Endothelium-dependent contractions are mediated by endothelial prostaglandins                  [@B92]
  Incorporation of the acronym: EDCF                                                             [@B56]
  Chemical nature of EDRF as NO                                                                  [@B108]
  Earliest confirming reports                                                                    [@B76]; [@B70]
  Identification of L-arginine as the precursor of NO                                            [@B107]
  Isolation of endothelin                                                                        [@B155]
  Incorporation of the term: EDHF                                                                [@B147]
  Endothelial release of a diffusible hyperpolarizing substance                                  [@B42]
  Influence of perivascular adipose tissue on smooth muscle responsiveness                       [@B128]
  Assignment of a paracrine role to adventitial cells                                            [@B33]
  Adventitium-derived relaxing factor coined as ADRF                                             [@B82]
  Demonstration that ADRF hyperpolarizes smooth muscle cells                                     [@B139]
  Incorporation of the acronym: PVAT                                                             [@B52]
  Existence of a procontractile transferable substance from PVAT                                 [@B55]
  *Tunica adiposa* as the fourth layer of the vascular wall histologically acknowledged          [@B17]
  Incorporation of the term: perivascular adipocyte-derived constricting factor PVCF             [@B51]
  Incorporation of the term: adipocyte-derived hyperpolarizing factor ADHF                       [@B146]
                                                                                                 

The Endothelial Inside-To-Outside Conception
============================================

Although endothelial regulation is today profoundly integrated in biomedical culture, this has not always been so. During most of last century, the intimal endothelium was considered a mere sort of tapestry with no physiological activity. Electron microscopist, Florey referred to these cells as "*nucleated cellophane*" cells ([@B46]). It is of justice to mention, however, that one of the early electron microscope pioneers, [@B116], who also observed the endothelium, intuitively suggested that transmitter substances present in the blood might be conveyed to the luminal side of endothelial cells and forwarded to smooth muscle cells. Although EDRF, later identified as NO, has gained the attribute of the canonical substance derived from the endothelial cells, it must be emphasized that, strictly speaking, the discovery of prostacyclin by Vane's group ([@B93]) represented the turning point between Florey's useless "cellophane-like" cells and a fully functional paracrine cell. The report on the newly discovered prostacyclin (which they still referred to as PGX) emphasized that is locally produced within the arterial wall and should play a role in the control of local vascular tone ([@B93]). They did not pinpoint any specific part of the vessel responsible for the formation of this autacoid (the term used to refer to these local mediators). A forthcoming publication dealt with the ability displayed by the different tunicae of the vessel wall to release prostacyclin. This showed that prostacyclin was highest in the endothelial layer, thus endowing the endothelium a role in the local control of vascular tone ([@B94]).

Prostacyclin production was regarded for its anti-aggregating properties and endothelial impairment was considered as a problem of hemostasis, rather than a vasomotor one. This scenario radically changed in 1980 when [@B48] demonstrated that endothelial cells play an obligatory role in the relaxation of arterial smooth muscle when stimulated by acetylcholine and introduced the term *endothelium-derived relaxing factor* and its acronym *EDRF* ([@B21]). EDRF was identified as NO in 1987 by [@B108], and immediately confirmed by [@B76], as well as [@B70].

An independent confirmation of the obligatory roles of the endothelium in acetylcholine relaxation after Furchgott's seminal paper was reported by [@B29], who also initiated the discovery of the "saga" of substances that vasodilate in an endothelium-dependent manner. They also showed that the endothelium is a source of substances that mediate contractile reactivity of the smooth muscle via the discharge of diffusible material acting just in an opposite manner to that of EDRF ([@B121]).

Rubanyi together with Hickey, using a setup intended to uncover the chemistry of Furchgott's factor, found a peptidic transferable substance that actually had contracting properties ([@B66]). This was later characterized and named endothelin ([@B155]). Gillespie proposed to use the acronym EDCF to distinguish it from EDRF ([@B56]).

Vanhoutte found difficult to assume that endothelin was the only substance behind endothelium-dependent contractions ([@B137]). A previous paper actually showed that endothelial cyclooxygenase generates vasoconstrictor prostaglandins ([@B92]), which were specifically ascribed to TXA~2~ ([@B2]). [@B63], in the late eighties, demonstrated that smooth muscle cells possess common binding sites for TXA~2~ and various other prostaglandins, including PGI~2~, which worked as high affinity receptors for TXA~2~ and as low affinity for the rest of prostaglandins ([Figure 2](#F2){ref-type="fig"}). They proposed that these common receptors may account for the contraction elicited by TXA~2~, but did not discuss the possible effects of other prostaglandins when binding to the low affinity site of the TXA~2~ receptor. This paper, however, inspired the idea that, in some cases, PGI~2~ could preferentially activate common-prostaglandin TXA~2~ receptors rather than the natural PGI~2~ receptors. This was taken to the physiological arena by Rapoport's group ([@B149]). The "multiprostaglandin" TXA~2~ receptor shown by Hanasaki and Arita was the basis for the proposal that PGI~2~ serves as the mediator underlying EDCF ([@B114]).

![Hanasaki and Arita's early vision of prostaglandin's action on smooth muscle cell receptors was a prelude of much research on the role of different prostaglandins, and most especially prostacyclin, acting as a vasoconstrictor and, thereby, functioning as an endothelium-derived contracting factor. Thromboxane A2 (TXA~2~), prostaglandins (PGs), smooth muscle cell (SMC). Modified from [@B63].](fphys-10-00729-g002){#F2}

At some point, it became obvious that EDRF (later NO) and prostacyclin were not enough to account for all the relaxing attributes of the vessels ([@B27]). Another evidence that did not fit in the endothelium-derived vasoactive release scheme was the long known observation that acetylcholine-mediated vasodilation was detectable, not solely on the neighboring regions, but also lengthwise the vessel wall exceeding the notion of "paracrinity" ([@B67]). There had to be another unknown mechanism. [@B12] forwarded the possible presence of a substance produced by endothelial cells, which causes hyperpolarization. This was coined with the term "endothelium-derived hyperpolarizing factor" (EDHF) ([@B147]). [@B42] carried out experiments aimed to bioassay the substance(s) causing hyperpolarization and provided evidence of the diffusible nature of EDHF. In 1998, [@B37] demonstrated that hyperpolarization could be due to K^+^ coming from the endothelial cell. There was indeed a K^+^ efflux from the endothelium secondary to a cholinergic activation. This cationic escape was demonstrated to be through endothelial calcium-dependent K^+^ channels. It was also shown that this cation, once present in the extracellular liquid, elicits hyperpolarization through inwardly rectifying K^+^ channels and the activation of a Na^+^/K^+^-ATPase.

As we have seen, the problem posed by some on the necessity of a third vasodilating factor (NO and prostacyclin being the other ones) to explain all sorts of relaxing phenomena, had been successfully addressed with EDHF. However, the "remote" acetylcholine vascular relaxation described by [@B67], had no satisfactory answer on the basis of EDHF. It had to be admitted that the change in membrane potential could be transmitted electrotonically through discrete connecting structures in the membranes named myoendothelial gap junctions ([@B129]). The spread of hyperpolarization has been studied in depth by Segal and Duling's group ([@B124]). Therefore, the problem of phenomena difficult to reconcile with the endothelium-derived vasoactive release scheme transmission was solved. Moreover, with myo-endothelial gap junctions in the scene, an EDHF as a paracrine mediator is not necessary after all and the term EDH, rather than EDHF, is currently recommended ([@B43]).

Beyond the Smooth Muscle Wall: New Paracrine Cells
==================================================

For decades, the leader of the paracrine control of the vessel's function was the luminal endothelium, and NO the main character. The other side of the vessel, the abluminal layer had received very little attention. Some histologists and pathologists claim that the *tunica adiposa* should be considered together with the classic *tunica intima, tunica media* and *tunica adventitia* ([@B17], [@B16]). Interestingly, this claim has a functional background rather than a histological one. In this way, perivascular adipose tissue (PVAT), which had always been considered as "extravascular," is increasingly considered an "intravascular" structure fundamentally composed by adipocytes, and also macrophages, fibroblasts, dendritic cells, pericytes, endothelial cells, and nerve endings ([@B132]).

The Paracrine Roles of Adventitial Fibroblasts
==============================================

One of the reasons why the adventitia had been persistently overlooked is the fact that it is technically very hard to remove ([@B74]). Thus, it is far more difficult to investigate its roles in the same way as with the endothelium, in which removal is fairly easy. Most frequently, the *tunica adventitia* has been considered simply as a passive scaffolding of the vessel. Possibly, the study carried out by [@B106] was the earliest to propose an active role of the adventitia in the regulation of vascular function by showing the existence of a powerful superoxide-generating system within this layer. Shortly before Pagano's introductory paper ([@B106]), another suggestive study was published. This one emphasized that the adventitia could work as functional barrier against endothelial NO ([@B131]). The study carried out by Pagano on the production of superoxide by the adventitia was followed by a number of clarifying reports. It was shown that the superoxide generating enzyme, NADPH oxidase is located within the fibroblasts of the *tunica adventitia* ([@B105]). The barrier identified by Steinhorn was ascribed to superoxide produced by fibroblasts, which would inactivate NO and therefore act as a chemical barrier ([@B142]). In 1999, adventitial superoxide was "officially" established as a paracrine player in the control of the vessel wall ([@B33]). In this way, the fibroblast of the adventitia could be considered a paracrine cell in the control of vasomotion.

It is obvious that to carry out experiments aimed to understand how the adventitia contributes to the regulation of vascular tone it is important to be able to remove it properly. The technical problems to obtain vessels lacking adventitial cells have been solved using different procedures. For example, [@B59] combined physical removal with a collagenase treatment. They were able to verify that when the *tunica adventitia* was present, smooth muscle contractions were stronger and endothelium-dependent relaxations weaker. These experiments unmistakably proved that the adventitial layer had a role in the regulation of vasomotion ([@B59]). In this case, again superoxide ([@B115]), and more recently hydrogen peroxide ([@B14]) were considered responsible for the influences the adventitia has on endothelial function. Additionally, fibroblasts have been shown to produce endothelin-1. Therefore, this peptide can be added to the relatively short list of fibroblast-derived paracrine substances ([@B5]).

Perivascular Adipose Tissue, a New Era in Vascular Research
===========================================================

In contrast to the adventitia, PVAT offers little resistance to removal. Ironically, this caused that the vasoactive roles of perivascular fat were always missed. On the assumption that PVAT is a extraneous tissue to the vessel, it has been always removed on a routine basis. Worse, it has been considered a diffusion barrier against vasoactive substances aimed at "authentic" vascular tissue. This situation has now changed and we are witnessing a rush for PVAT research. However, it must be said that it has been known for years that adipocytes are able to produce hormones involved in the control of energy balance, the so-called, *adipokines* ([@B68]). What was really new in the vascular field was that adipocytes might work as paracrine cells by releasing vasomotor transferable mediators. Evidently, this could only take place when adipose tissue is next to the vessel wall, something that happens only with adventitial fat or PVAT ([Figure 1](#F1){ref-type="fig"}). In this case, adipocytes would co-regulate smooth muscle tone together with intimal endothelial cells. By demonstrating that the fat tissue around the adventitia releases a transferable substance that alters the vessel tone, this novel idea was materialized. In 2002, [@B82] demonstrated for the first time the existence of a diffusible substance of PVAT origin, which they called ADRF, the acronym of "*adventitium-derived relaxing factor*," a name that strongly recalls that of EDRF ([@B21], [Table 1](#T1){ref-type="table"}). In an ensuing publication, the "A" of ADRF was for "adipocyte" rather than "adventitium" ([@B139]), thus emphasizing the role of adipose tissue over conventional adventitial cells. In the earliest publication of the group it was shown that the contractile force elicited by aortic rings upon phenylephrine, angiotensin II or serotonin, assessed by cummulative dose-response curves, was systematically weaker when the vessel was examined with its perivascular fat preserved than when it was removed. It was also demonstrated that a solution obtained from PVAT-incubated specimens caused relaxations when supplied to vessels completely devoid of fat and precontracted with any of the mentioned vasoconstrictors ([@B82]; [@B139]).

The idea of a functional perivascular adipocyte has generated a novel manner in which we regard the vessel, both anatomical (regarding PVAT as the fourth layer of the vascular wall), physiological (perivascular adipocytes acting together with the endothelial cell) and even pathophysiological: the so-called "perivascular adipose tissue dysfunction" ([@B61]). Even more, the *adventitia/media thickness* factor (which includes PVAT) rather than the conventional parameter *intima/media thickness* has been recommended for ultrasonographic measurements since the former is regarded more precise than the latter in relation to cardiovascular risk ([@B127]).

Although PVAT is an attractive alternative to explain the paracrine functions of the vessel, there are substantial dissimilarities between perivascular adipocytes and endothelial cells. Thus, it would be naïve to consider adventitial fat as the *new endothelium*. Namely, these differences are: (a) the most evident, but most important, is that endothelial cells are exposed to the effect of the blood stream and this determines the existence of a direct sensing of the mechanical conditions (pressure and shear stress) of the blood. PVAT, in contrast, is more exposed to tissue inflammatory conditions. (b) Provided there is no injury, the endothelium is always present. By contrast, PVAT is missing in a vast portion of the circulatory system: all the capillary circulation (with the exception of that serving adipose tissue) lacks adipose tissue. (c) Adipose tissue normally surrounds large conduit arteries and veins as they run through adiposity, however, fat is usually left behind once the vessel comes into or leaves the target organ, a fact that obviously does not happen with endothelium. (d) While PVAT is made out of many cell types, the intimal layer is made solely by endothelial cells and subendothelial fibroblasts. Conversely, both tissues share some aspects. For example, the phenotype of PVAT is different depending on the site of the fat store ([@B19]; [@B119]; [@B104]; [@B101]) and this affects the way it regulates the tone of the surrounding vessel ([@B57]). This evokes the heterogeneous ability of generating different endothelium-dependent dilating or contracting substances displayed by the endothelium depending on the vascular region ([@B30]).

Another common attribute of PVAT and the endothelium is the capability to synthesize NO and prostaglandins ([@B26]; [@B18]). Regarding NO, various groups have detected the expression of the endothelial isoform of NO synthase (eNOS) in the PVAT surrounding the thoracic aorta ([@B8]; [@B153]; [@B140]) as well as the ability of this tissue to release NO. This PVAT-derived NO (PDNO) is released into the interstitial fluid and diffuses into the capillaries causing vasodilatation ([@B87]), which is key in the vasoprotective function of the endothelium ([Figure 3](#F3){ref-type="fig"}). Victorio and coworkers demonstrated that PVAT presents heterogeneity in its eNOS expression according to the vascular region studied: thoracic or abdominal aorta ([@B140]). In contrast, endothelial eNOS expression remains the same along the aorta.

![In physiological conditions, eNOS is expressed in PVAT and produces NO. PVAT-derived NO diffuses into the capillaries protecting endothelial function. In pathological conditions, the production of PDNO is compromised due to superoxide overproduction in PVAT, which is formed by NADPH oxidase and uncoupled eNOS. Activity of NADPH oxidase is increased in this tissue. Overproduction of superoxide anion by uncoupled eNOS or NADPH oxidase leads to peroxynitrite formation, which in turn produces oxidation of BH4 to BH2, an essential cofactor of eNOS. PVAT: perivascular adipose tissue, VSMC: vascular smooth muscle cells; EC: endothelial cells; eNOS: endothelial isoform of nitric oxide synthase; NO: nitric oxide; PDNO: PVAT-derived NO; ONOO^-^: peroxinitrite; O~2~^-^: superoxide anion; L-Arg: L-Arginine; BH4: tetrahydrobiopterin; BH2: dihydrobiopterin; p67^phox^, p47 and p22 and NOX2: NADPH oxidase subunits.](fphys-10-00729-g003){#F3}

As for the other isoforms of NO synthase, the inducible isoform (iNOS) has been identified under basal conditions in very low levels in white adipose tissue ([@B117]; [@B38]) but clearly induced after LPS treatment ([@B117]). Neuronal NO synthase (nNOS) was not found in Elizalde's study ([@B38]), but, in a study specifically focused in PVAT of mouse aorta, mRNA expression of the three isoforms of NO synthase, eNOS, nNOS and iNOS was detected ([@B153]).

In pathological conditions, the production of PDNO may be compromised due to superoxide overproduction in PVAT. This tissue, together with other vessel wall components (endothelium, smooth muscle and adventitia) is a source of vascular superoxide. This production of superoxide anion leads to oxidative stress, which is an important part of endothelial dysfunction. Although NADPH oxidase is the main superoxide-producing enzyme, the uncoupling of eNOS also produces this anion. It has been shown that under pathological conditions, NADPH oxidase activity in PVAT is increased ([@B86]), as well as the expression of the subunits of the NADPH oxidase complex such as p67phox, p22phox, p47phox or Nox2 ([@B55]; [@B32]; [@B112]). In addition, PVAT displays an increased mRNA expression of the Ncf2 gene that encodes for the p67phox subunit ([@B75]). All this contributing to vascular superoxide production and endothelial dysfunction ([Figure 3](#F3){ref-type="fig"}).

Uncoupled eNOS ([Figure 3](#F3){ref-type="fig"}) no longer produces NO, but superoxide. NOS uncoupling has been demonstrated in numerous conditions and tissues, of which PVAT is not an exception ([@B153]). Uncoupled eNOS considerably contributes to endothelial dysfunction, since it not only reduces NO production, but also potentiates the preexisting oxidative stress. The situation is further aggravated because the overproduction of superoxide anion by uncoupled eNOS leads to peroxynitrite formation, that in turn depletes tetrahydrobiopterin (BH4), which is an essential cofactor of eNOS. In PVAT, oxidation of BH4 to BH2 (dihydrobiopterin), is likely to be a major cause of eNOS uncoupling and endothelial dysfunction ([@B153]).

More that a decade before Löhn's publication, Soltis and Cassis published the earliest report suggesting that PVAT influences the vessel's contractility ([@B128]). Interestingly, they used the term "perivascular adipose tissue" for this early paper, a term that has been adopted to refer to the *tunica adiposa*. Perhaps, because of this this, Soltis and Cassis' work has been occasionally misunderstood and quoted as the first one to demonstrate the existence of a prorelaxing function of PVAT. In fact, what Soltis and Cassis show is PVAT as the physical support of neurotransmitter reuptake by sympathetic fibers. These endings can be found in PVAT and in the adventitia ([Figure 1](#F1){ref-type="fig"}). These two researchers noted that, in the absence of PVAT, there was an abolishment of noradrenaline-mediated contractions. The sensitivity to noradrenaline was also decreased when arterial rings had a preserved PVAT. They showed that this is produced by the reuptake of noradrenaline by PVAT and suggested that this is carried out by the nerve endings within PVAT present in the synaptic gap. This causes a weaker effect of the drug. However, at no time they asserted that PVAT produces any kind of anticontractile or relaxing substance. Actually, their experiment was only possible to carry out with noradrenaline, which suffered reuptake. It did not work with phenylephrine or potassium, which did not undergo reuptake. Much more recently, the interaction between sympathetic innervation, PVAT and smooth muscle relaxation has received further attention in a work showing that PVAT adipocytes can transport and store noradrenaline ([@B10]) and that this acts as a reservoir of the sympathetic nerve ending release of the catechoamine, therefore preventing smooth muscle contraction ([@B122]).

The Nature and Physiological Properties of PVAT-Derived Factors
===============================================================

The substances produced by adipocytes are collectively known as adipokines ([@B133]). Today there are more than one hundred established adipokines ([@B62]). Considering that adipocytes represent more than sixty percent of the adiposity and their enormous hormone-synthesizing capability, it is not unreasonable to believe that released adipokines from adipocytes located in the vicinity of the artery, i.e., PVAT, travel to the *tunica media*, or even the *intima*, and alter, in some way, vascular function ([Figure 1](#F1){ref-type="fig"}). Today, this paracrine crosstalk between PVAT and its artery, or "vasocrine" communication ([@B156]) is fully recognized by the scientific community ([@B97]). Amid all the recorded adipokines, many have vasoactive power to a certain degree apart from their central function. From the point of view of the vascular physiologist, adipokines can be classified as follows:

1.  Unidentified substances from the perivascular environment

2.  Adipocyte-derived vasoactive hormones

3.  Energy balance adipokines

4.  Free radicals

5.  Adipocytokines

It is also possible to organize vasoactive adipokines on the basis of the differential action on smooth muscle (direct pro- or anticontractile effect) or on endothelial cells (stimulating or inhibiting the release of endothelium-derived vasoactive substances).

(a) Unidentified Substances From the Perivascular Environment
-------------------------------------------------------------

These have been solely investigated in PVAT and in no other fat depot. The experiments that led to the knowledge of the presence of this kind of substances basically consist in the transfer of a physiological buffer from isolated arteries in which PVAT had been removed ([@B85]) or preserved ([@B82]) to another artery devoid of PVAT. Alternatively, dose-response curves of a vasoconstrictor are carried out in segments with, versus without, PVAT. It this case, more powerful constrictions take place when PVAT is removed. Consequently, these unidentified PVAT-borne substances are sometimes referred to as anti-contractile substances, but more frequently as ADRFs. They are probably released by PVAT and no other fat store but this point has never been studied so far.

Initial reports on rat aorta show that ADRFs relax the vessel via hyperpolarization by opening different kinds of potassium channels on the membrane of the smooth muscle ([@B82]; [@B139]). More specifically, K^+^~ATP~ channels have been shown to be involved and opening appears to be dependent on extracellullar calcium, protein kinase A and tyrosine kinase, but independent of the presence of the endothelium or perivascular nerves ([@B82]; [@B36]). In the rat mesenteric artery, K^+^~V~ delayed rectifier channels were shown to hyperpolarize the smooth muscle cell membrane when opened by the transferable substance ([@B139]). On the other hand, in human arteries, K^+^~Ca~ channels are the target of ADRF ([@B53]). However, the same researchers report that PVAT does not diminish contractions of rat mesenteric arteries when elicited by electrical stimulation ([@B55]). They reasoned that this is specific to PVAT's perivascular nerve endings where NAD(P)H oxidase synthesizes superoxide anion and, as a result of this, PVAT mediates contraction instead of relaxation ([@B55]). In a later review, they suggested to use the term *perivascular adipocyte-derived constricting factor* (PVCF) for these type of contractile substances ([@B51]). More recently, [@B90] have used the acronym ADCF. It was suggested that substances different from oxygen radicals could act as PVCFs. In this sense, PVAT might have a double role on the vessel surrounded: anti-contractile and pro-contractile ([@B51]). Research carried out later uncovered new substances acting as PVCFs after electrical stimulation, like angiotensin II ([@B83]).

Further experimentation focused on anti-contractile transferable substances have shown that the factor released by rat aortic PVAT works through two mechanisms ([@B54]). One of the mechanisms is endothelium-independent but, in contradiction to that previously reported in the same vessel which relies on K^+^ channels ([@B82]; [@B139]), this one depends on oxygen peroxide. The other mechanism is actually K^+^ channel-dependent but based on the opening of K^+^~Ca~, but not K^+^~ATP~, channels and, unlike the preliminary report on rat aortic PVAT, this one is endothelium-dependent ([@B54]).

The chemical nature of PVAT is still a matter of debate. Löhn and Dubrovska, by using specific inhibitors, discarded NO, prostaglandins and other mediators ([@B82]; [@B36]). Oxygen peroxide was the first substance proposed ([@B54]), followed by angiotensin 1-7 ([@B80]). By the same time, the gas hydrogen sulfide was suggested, in this case acting via K^+^~ATP~ channels ([@B40]). Subsequently, another research team showed that palmitate, acting through K^+^~V~ channels, might be the ADRF ([@B81]). Finally, adiponectin, which had been previously discarded as a candidate to ADRF ([@B44]), was revisited in two papers published in 2013 demonstrating that adiponectin acts as an ADRF by eliciting anticontractile effects through the opening of K^+^~Ca~ channels ([@B84]; [@B146]). One common feature in the quest for the identity of ADRF is K^+^ channel opening as well as smooth muscle hyperpolarization ([@B36]). The acronym ADHF was proposed by Weston, who also coined the term EDHF ([@B147]) to refer to adipocyte-derived hyperpolarizing factors(s) ([@B146]).

(b) Adipocyte-Derived Vasoactive Hormones
-----------------------------------------

These are the well known vasoactive hormones such as angiotensin II, noradrenaline or NO. The novelty relies in that, interestingly, they can be generated by adipose tissue as well. So far, classic vasoactive substances that are, at the same time, adipokines are the following:

1.  NO. When generated by adipose tissue different from PVAT ([@B117]) and from PVAT ([@B26]).

2.  Prostacyclin. From general adipose tissue ([@B9]); from PVAT ([@B18]).

3.  Prostaglandin E~2~. From general adipose tissue ([@B125]); from PVAT ([@B89]; [@B102]).

4.  TXA~2~. From general adipose tissue ([@B41]); from PVAT ([@B89]; [@B90]).

5.  Endothelin-1. From general adipose tissue ([@B135]); from PVAT ([@B89]).

6.  Angiotensin II. From general adipose tissue ([@B123]); from PVAT ([@B49]).

7.  Aldosterone. From general adipose tissue ([@B100]); no report on PVAT.

8.  Noradrenaline. From general adipose tissue ([@B138]); from PVAT ([@B11]).

In some cases, such as that of prostaglandins, the adipocyte origin has been known for decades ([@B125]), but only recently these have been found in PVAT ([@B18]; [@B89]; [@B90]).

One interesting issue is the ability of PVAT to release factors that are normally ascribed to endothelial cells. This has significant consequences, especially in obesity, in which hypertrophied visceral fat stores might produce some vasoconstrictors, like endothelin-1 or TXA~2~, the origin of which now we realize that is not only endothelial. Also, it is important to be aware of the fact that PVAT adipocytes are perfectly able to release angiotensin II or aldosterone ([@B39]; [@B100]) and add up to the regular kidney production.

Another "endothelium-like" property of PVAT is its ability to produce NO. This initially seemed to be conflicting with the well known vascular dysfunction of obesity. The conflict was solved by [@B58] who proposed that PVAT-derived NO, at least temporarily, plays an adaptive role in the early stages of obesity. Conflicting or not, we now know that PVAT is perfectly able to synthesize NO. It has been demonstrated that activation of β3 receptor in PVAT's adipocytes by sympathetic nerve endings induce PKA-dependent NOS activation, thereby producing NO which elicits smooth muscle cell relaxation ([@B13]). Furthermore, PVAT-derived NO appears to accompany the beneficial effects of physical exercise ([@B91]).

It is known that acetylcholine, among other agonists, can stimulate adipocytic metabolism ([@B125]). In this line, it has been proposed that acetylcholine stimulation of PVAT would be capable to produce NO and relax the surrounded artery, even if denuded of endothelium. ([@B153]). In this sense, PVAT would qualify as a real controller of vascular tone. This point has not been fully confirmed ([@B69]; [@B140]) but it would mean that PVAT could support the endothelium, or even replace it in pathological conditions.

(c) Energy Balance Adipokines
-----------------------------

They are adipokines implicated in energy homeostasis. Therefore, production is altered in type II diabetes and in obesity and are involved in cardiovascular physiology and pathophysiology. These kind of adipokines comprises leptin, adiponectin, resistin, omentin, vaspin, visfatin and chemerin. Leptin receptors are present on endothelial cell membranes ([@B126]). This means that vascular walls are potential targets of this hormone and posses the ability to generate NO ([@B47]). Publications on the paracrine roles of leptin are contradictory. Initial information indicated that leptin causes NO-dependent ([@B77]) or -independent ([@B96]) vasodilation. This is not easy to fit with epidemiological research repetitively presenting leptin as related to the cardiovascular problems of obesity ([@B88]). Leptin released by PVAT elicits endothelial dysfunction in obese, but not lean, animals ([@B111]). However, many studies propose leptin as the ADRF acting via endothelial cells ([@B25]; [@B50]; [@B130]). It is a paradox that leptin elicits vasodilation in an NO-dependent manner and simultaneously diminishes endothelium-dependent relaxations ([@B78]).

Adiponectin is known as the adipokine that competes with leptin's actions ([@B88]). Excessive release of the latter and scarcity of the former is related with the unwanted cardiovascular conditions occuring in obesity ([@B88]). Adiponectin has shown endothelial NO stimulating activity ([@B20]; [@B64]) and NO-dependent vasodilating actions ([@B152]). Previous vasodilating evidences of adiponectin have led to the proposal that this adipokine might be the ADRF ([@B84]; [@B146]).

Resistin, omentin and vaspin have not been investigated with regard to PVAT. However, it is known that resistin impairs endothelial function ([@B79]), omentin elicits minor endothelium-dependent relaxations ([@B154]) and vaspin improves endothelium-dependent relaxations elicited by acetylcholine ([@B72]). In contrast with these three, chemerin has been demonstrated to be generated by PVAT, with pro-contractile ([@B144]) as well as endothelium dysfunctioning ([@B98]) properties, acting possibly via NAD(P)H oxidase ([@B99]) and potentiating the effects of adrenergic nerve endings within PVAT ([@B24]). Visfatin, when obtained from PVAT, exhibits no effects on contractility ([@B143]) but, in non-PVAT set ups, visfatin has shown to cause an important impairment of endothelial function ([@B134]). Finally, chemerin has been identified as derived from PVAT. It has pro-contractile ([@B144]) as well as endothelium dysfunctioning ([@B98]) properties, acting possibly via NAD(P)H oxidase ([@B99]) and potentiating the effects of adrenergic nerve endings within PVAT ([@B24]).

(d) Free Radicals
-----------------

The opening publication connecting PVAT with free radicals was that already commented by Gao and coworkers in which oxygen peroxide acts as a vasodilator ([@B54]) and superoxide as a PVCF ([@B55]). It appears contradictory that reactive oxygen species (ROS) function as vasodilatory in some instances and vasoconstrictve in others. In this sense, a recent report highlights the dismutation of procontractile mitochondrial superoxide into anticontractile oxygen peroxide as a mechanism to reconcile the conflict between oxygen peroxide being, or not, relaxing ([@B22]). This superoxide-generating potential of PVAT is related to the anti-contractile properties of this tissue in obesity ([@B60]). Also to endothelial dysfunction in obesity as well ([@B75]). There is sufficient evidence to presume that NAD(P)H oxidase is the enzyme that synthesizes superoxide in PVAT ([@B55]; [@B141]). [@B141] demonstrated the existence of a cause-effect association between TNFα and ROS production in PVAT. More recently, Costa and others linked their previously mentioned mitochondrial superoxide issue ([@B22]) to TNFα-induced oxidative stress ([@B23]).

(e) Adipocytokines
------------------

These are cytokines synthesized and released specifically by adipocytes ([@B133]). Adipocytokines are produced during inflammation. They can activate inducible NOS ([@B4]) and, at the same time, impair endothelium-dependent relaxations ([@B7]). PVAT adipocytes can release adipocytokines. Actually, PVAT is a fat depot with a demonstrated proinflammatory phenotype and releases more adipocytokines as compared with the subcutaneous depot ([@B19]). This is true for the healthy non-obese individual ([@B19]), but is aggravated in obesity ([@B65]). [@B7] published years ago a paper entitled "*Anti-EDRF effect of tumor necrosis factor*." Based on the proinflammatory features of PVAT, it appears that this fat store produces anti-EDRF (anti-NO) substances. This has also been shown in myographic setups of arteries analyzed with or without PVAT ([@B110]) and specifically with the adipocytokine, TNFα ([@B34]). It must be highlighted that some reports disagree with the idea that PVAT is a harmful tissue merely because it exhibits a background release of adipocytokines. For example, some maintain that PVAT does not elicit endothelial dysfunction ([@B120]) and numerous studies show that endothelium-dependent relaxations are perfectly normal in arteries with PVAT when weighed against those without PVAT ([@B75]; [@B89]). Furthermore, a recent report indicates that the adipocytokine IL-6 seems to regulate the adipose beneficial changes associated to physical activity ([@B145]). Endothelial dysfunction appears in vessels from obese animals ([@B75]; [@B89]). The obese, consecutively, reveal lower anticontractile properties which can increase under a cytokine antagonist treatment ([@B60]).

[Table 2](#T2){ref-type="table"} summarizes the substances released by PVAT specifying whether they are anti-contractile (relaxant) or pro-contractile. In some cases, the latter cause endothelial dysfunction of the surrounded vessel.

###### 

Relaxing and contracting adipokines produced by PVAT.

  Adipokine          Contracting (C) or relaxing (R) properties   References
  ------------------ -------------------------------------------- ----------------
  Unknown            R                                            [@B82]
  Superoxide anion   C                                            [@B55]
  Angiotensin 1-7    R                                            [@B80]
  H~2~S              R                                            [@B40]
  Angiotensin II     C                                            [@B83]
  NO                 R                                            [@B58]
  Leptin             C R                                          [@B111] [@B50]
  Visfatin^1^        C                                            [@B134]
  Adiponectin        R                                            [@B84]
  Palmitate          R                                            [@B81]
  Prostacyclin       R                                            [@B18]
  PGE~2~             C R                                          [@B89] [@B102]
  TXA~2~             C                                            [@B89]
  Endothelin-1       C                                            [@B89]
  Chemerin           C                                            [@B144]
  Noradrenaline      C                                            [@B11]
  TNFα               C                                            [@B141]
  Vaspin^1^          R                                            [@B72]
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Vessel not incubated with PVAT but with the adipokine.

New Pathways in the Regulation of Vascular Motion
=================================================

Cells within the vascular environment keep surprising us for their abilities to interplay. The archetypal notion of the regulation of the vascular wall involving the classical mediators prostacyclin, NO, EDHF or EDCFs represented an outward communication. The advent of the always overlooked PVAT, turned over the whole concept into an inward signaling. It is worth to remember that an interaction of endothelial cells and adipocytes was proposed in the late eighties, before PVAT was known as such ([@B109]) and Richelsen published a review supporting the concept that adipocytes provide the endothelial cell with arachidonic acid for the synthesis of prostaglandins and that the release of these substances requires the action of both kind of cells ([@B118]). Since these initial proposals our understanding of the cross-talk between the different cells of the vascular milieu has experimented a remarkable growth. Some of these interactions can reach a high level of complexity, involving the nervous system or blood hormones and various types of vascular cells. The following are examples of these interactions:

1.  Sympathetic nerve endings can, via PVAT adipocyte β3 receptors, activate adiponectin release which activates adiponectin receptors in endothelial cells that, in turn, elicit an AMP kinase-dependent NOS activation with NO release causing smooth muscle cell relaxation ([@B31]; [@B150]).

2.  Circulating atrial natriuretic peptide can activate PVAT adipocyte ANP receptors to cause PKG-dependent adiponectin release which follows the same route as above ([@B151]).

3.  Smooth muscle cell-derived ROS is released to the circulation as blood 4-hydroxynonenal. This, in the adipocyte, stimulates adiponectin release which inhibits NAD(P)H oxidase in endothelial cells, thereby protecting endothelial NO and, indirectly promoting the relaxation of the smooth muscle ([@B6]).

An additional pathway involving the signaling of endothelial cells over PVAT adipocytes has also been investigated. Specifically, the potential interaction of endothelium-derived NO on the neighboring PVAT as compared to that on smooth muscle cells. This was however, not confirmed ([@B103]). Finally, an unanticipated route of PVAT interactions with its immediate environment is the demonstration of a sensory nerve terminal-dependent (rather that sympathetic) activation of PVAT's adipokine release with vasomotor consequences ([@B1]). [Figure 4](#F4){ref-type="fig"} summarizes the intercellular communication aimed to the control of smooth muscle tone.

![Modern patterns of "outside-to-inside" and "inside-to-outside" communication exhibited by PVAT adipocyte/sympathetic nerve endings-endothelial-smooth muscle cell- interactions. The three-way crosstalk so far discovered involves endothelium-derived NO (EDNO) on the luminal side, and on the perivascular side: angiotensin 1-7 (AT1-7), leptin, TNFα, reactive oxygen species (ROS), adiponectin, NO synthase (NOS), PVAT-derived NO (PDNO) and noradrenaline (NA) from the nerve endings.](fphys-10-00729-g004){#F4}

Author Contributions
====================

EN compiled information and references and wrote the manuscript. SL assisted with reference managing, designed the figures, and assessed adequacy of the draft.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

[^1]: Edited by: James B. Hoying, Cardiovascular Innovation Institute (CII), United States

[^2]: Reviewed by: Carlos R. Tirapelli, University of São Paulo, Brazil; Kathleen Ann Martin, Yale University, United States

[^3]: This article was submitted to Vascular Physiology, a section of the journal Frontiers in Physiology
